Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
FDA-approved: Replacement of extracellular fluid losses in patients who require fluid resuscitation or maintenance, particularly in metabolic acidosis or mild to moderate acid-base disturbances.,Off-label: Not commonly used off-label; may be used in specific electrolyte imbalances or perioperative settings where balanced crystalloid is preferred.
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable (components are endogenous substances; half-life reflects renal clearance and volume status, typically 2-4 hours for sodium and chloride in euvolemic patients).
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Acetate and gluconate are metabolized primarily in the liver and peripheral tissues to bicarbonate ions. Electrolytes are excreted or reabsorbed via renal mechanisms.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal: 100% (electrolytes and buffer components are excreted unchanged by the kidneys; no biliary or fecal elimination).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
0% (electrolytes and buffer components are not protein-bound; free in plasma).
Negligible for electrolytes and dextrose (<5%).
Sodium: 0.15-0.3 L/kg (extracellular fluid space); Chloride: similar; Bicarbonate precursor (acetate/gluconate): distributed in total body water (~0.6 L/kg).
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100% (directly administered into bloodstream); not applicable to other routes.
Intravenous: 100%.
No specific dosage adjustment; use with caution in severe renal impairment due to risk of electrolyte imbalances and fluid overload.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific dosage adjustment; monitor for electrolyte disturbances and fluid overload.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Weight-based: 100-150 m L/kg/24 hours for maintenance; adjust based on clinical condition and electrolyte requirements.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to increased risk of fluid overload and electrolyte imbalances; start at lower end of dosing range and monitor closely.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
No FDA black box warning.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Use with caution in patients with congestive heart failure, severe renal impairment, hyponatremia, hyperkalemia, hypermagnesemia, or conditions predisposing to fluid overload.,May cause fluid and/or solute overload, pulmonary edema, or electrolyte disturbances.,Monitor serum electrolytes, fluid balance, and acid-base status during prolonged therapy.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hypersensitivity to any component.,Severe hyperkalemia or severe hypernatremia.,Patients with significant fluid overload or severe metabolic alkalosis.,Concurrent use with products containing calcium (risk of precipitation in IV line, though not directly contraindicated with this product, but caution).
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No known food interactions. However, oral intake may be restricted or modified based on underlying condition (e.g., bowel rest, NPO status).
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Isolyte S p H 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid and electrolyte replacement.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Isolyte S p H 7.4 constituents are normal components of body fluids and breast milk. No specific M/P ratio is available; however, there is no expected risk to the nursing infant when the solution is used as indicated.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Pregnancy may alter fluid and electrolyte requirements due to increased plasma volume and glomerular filtration rate. Dosing should be individualized based on maternal status; no fixed dose adjustment is necessary, but careful monitoring of volume status is recommended.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
ISOLYTE S p H 7.4 is a balanced isotonic crystalloid solution containing multiple electrolytes (sodium, potassium, magnesium, calcium, acetate, gluconate) and is buffered to p H 7.4. It is indicated for use as a replacement fluid in extracellular volume depletion (e.g., dehydration, burns, surgery) and for maintenance fluid therapy. Avoid use in patients with hyperkalemia, hypercalcemia, or severe metabolic alkalosis. The acetate and gluconate act as bicarbonate precursors, making it suitable for correcting mild metabolic acidosis. In patients with renal impairment, monitor electrolytes closely due to risk of accumulation. Do not confuse with ISOLYTE S without p H adjustment (which may have different buffer composition).
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution is given intravenously to replace lost fluids and electrolytes.,Tell your healthcare provider if you have kidney disease, heart disease, or any electrolyte imbalances.,Report any signs of fluid overload, such as shortness of breath, swelling in ankles or feet, or rapid weight gain.,Do not drive or operate heavy machinery until you know how this medication affects you.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for blood tests to monitor electrolyte levels.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S PH 7.4 IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S p H 7.4 is an isotonic crystalloid solution that expands intravascular volume and replaces extracellular fluid losses. It provides electrolytes (sodium, chloride, potassium, magnesium, acetate, gluconate) to maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs, typically 500-3000 m L/24 hours for adults.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S PH 7.4 IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S PH 7.4 IN PLASTIC CONTAINER is classified as Category C. Isolyte S pH 7.4 is a balanced electrolyte solution with no known teratogenic effects in humans. No fetal risks are identified in any trimester when used appropriately for fluid an. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.